RGENNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
REPLIGEN CORP
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 29, 2026
$176.43+1.01 (+0.58%)
Close on Oct 19, 2026
- Market cap
- $9.99B
- P/E (TTM)
- 205.2
- Dividend yield
- –
Share price
+$23.83 (+15.62%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
REPLIGEN CORP grew revenue 16.5% to $785.10M over the twelve months to Jun 30, 2026. Free cash flow was $111.97M, up 2.8% from a year earlier.
Revenue
$785.10M
+16.5% vs. a year earlier
Operating income
$64.61M
TTM Q2 2026
Free cash flow
$111.97M
+2.8% vs. a year earlier
EPS, diluted
$0.86
FY2025
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $9.99B
- P/E ratio
- 205.2
- Price to sales
- 12.73
- Price to book
- 4.73
- Dividend yield
- –
- Free cash flow yield
- 1.12%
Fundamentals
- Revenue
- $785.10M
- Net income
- $41.54M
- EPS, diluted
- $0.86
- Free cash flow
- $111.97M
- Book value per share
- $37.29
- Diluted shares
- 57M
Fifteen years at a glance
Fiscal years 2010 to 2025 and trailing twelve months, USD
Revenue
$785.10M+16.5% YoY
Gross profit
$422.67M+40.6% YoY
Operating income
$64.61M
Net income
$41.54M
EPS, diluted
–
Free cash flow
$111.97M+2.8% YoY
Reported periodTrailing twelve months